135 related articles for article (PubMed ID: 22359923)
1. [State of antioxidant system in patients with multiple sclerosis during therapy].
Smirnova LP; Krotenko NV; Grishko EV; Krotenko NM; Alifirova VM; Ivanova SA
Biomed Khim; 2011; 57(6):661-70. PubMed ID: 22359923
[TBL] [Abstract][Full Text] [Related]
2. [The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Kravtsov IuI; Kicherova OA
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(3):69-71. PubMed ID: 23612414
[TBL] [Abstract][Full Text] [Related]
3. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients.
Adamczyk-Sowa M; Pierzchala K; Sowa P; Polaniak R; Kukla M; Hartel M
J Physiol Pharmacol; 2014 Aug; 65(4):543-50. PubMed ID: 25179086
[TBL] [Abstract][Full Text] [Related]
4. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
[TBL] [Abstract][Full Text] [Related]
5. Antioxidative enzymes activity and malondialdehyde concentration during mitoxantrone therapy in multiple sclerosis patients.
Adamczyk-Sowa M; Sowa P; Pierzchala K; Polaniak R; Labuz-Roszak B
J Physiol Pharmacol; 2012 Dec; 63(6):683-90. PubMed ID: 23388485
[TBL] [Abstract][Full Text] [Related]
6. [Parameters of antioxidant protection in multiple sclerosis].
Krotenko NV; Alifirova VM; Ivanova SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):53-6. PubMed ID: 19891349
[TBL] [Abstract][Full Text] [Related]
7. Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients.
Likidlilid A; Patchanans N; Peerapatdit T; Sriratanasathavorn C
J Med Assoc Thai; 2010 Jun; 93(6):682-93. PubMed ID: 20572373
[TBL] [Abstract][Full Text] [Related]
8. [Redox-dependent processes in blood plasma, neutrophils and erythrocytes of patients with ovary cancer after polychemotherapy by CAP scheme].
Gening TP; Abakumova TV; Dolgova DR; Antoneeva II; Gening SO; Pirmamedova SS; Fomina AV; Vasil'eva EV
Antibiot Khimioter; 2014; 59(5-6):20-5. PubMed ID: 25552040
[TBL] [Abstract][Full Text] [Related]
9. Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis.
Keles MS; Taysi S; Sen N; Aksoy H; Akçay F
Can J Neurol Sci; 2001 May; 28(2):141-3. PubMed ID: 11383939
[TBL] [Abstract][Full Text] [Related]
10. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
Gusev EI; Boĭko AN; Pozer Ch
Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
[No Abstract] [Full Text] [Related]
11. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
12. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis.
Constantinescu CS; Freitag P; Kappos L
Mult Scler; 2000 Dec; 6(6):378-81. PubMed ID: 11212132
[TBL] [Abstract][Full Text] [Related]
13. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
[TBL] [Abstract][Full Text] [Related]
15. [Lipid peroxidation and antioxidant defence enzyme activity in multiple sclerosis].
Pasichna EP; Morozova RP; Donchenko HV; Vinychuk SM; Kopchak OO
Ukr Biokhim Zh (1999); 2007; 79(5):165-74. PubMed ID: 18357791
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
Rudick RA
Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
[TBL] [Abstract][Full Text] [Related]
17. Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
Johnson KP
Mult Scler; 1996 Jul; 1(6):325-6. PubMed ID: 9345409
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory treatment of MS in Slovenia.
Sega-Jazbec S
Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663
[No Abstract] [Full Text] [Related]
19. [The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy].
Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Ovcharov VV; Popova NF; Sinbukhova NI; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():101-10. PubMed ID: 17172244
[TBL] [Abstract][Full Text] [Related]
20. Enzymatic efficiency of erythrocyte antioxidant barrier and lipid peroxidation in children from families with high risk of early atherosclerosis.
Hapyn E; Czerwionka-Szaflarska M; Drewa G
Med Sci Monit; 2000; 6(1):112-6. PubMed ID: 11208296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
